Single-dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression.
نویسندگان
چکیده
aChange in Hamilton Depression Rating Scale (HDRS) (A) and Beck Depression Inventory (BDI) (B) mixed-model analysis results are noted on figures, with *P < .05 and **P < .01 on a last-observationcarried-forward paired t test (gray bar represents remission cut-off). The relationship between acute improvement after ketamine (day 1) vs improvement after 8 weeks of d-cycloserine treatment (C) is shown in a scatter plot across the HDRS (circle) and the BDI (triangle).
منابع مشابه
Ketamine for treatment-resistant unipolar depression: current evidence.
Currently available drugs for unipolar major depressive disorder (MDD), which target monoaminergic systems, have a delayed onset of action and significant limitations in efficacy. Antidepressants with primary pharmacological targets outside the monoamine system may offer the potential for more rapid activity with improved therapeutic benefit. The glutamate system has been scrutinized as a targe...
متن کاملLithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression
Ketamine and lithium both inhibit glycogen synthase kinase 3. In addition, lithium and ketamine have synergistic antidepressant-like effects at individually subeffective doses in rodents. We hypothesized that ketamine's antidepressant effects would be improved by therapeutic doses of lithium versus valproate and that serum lithium levels would positively correlate with ketamine's antidepressant...
متن کاملKetamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic.
BACKGROUND Ketamine has a rapid antidepressant effect in treatment-resistant depression (TRD). The effects on cognitive function of multiple ketamine infusions and of concurrent antidepressant medication on response rate and duration are not known. METHOD Twenty-eight patients with uni- or bipolar TRD were treated over three weeks with either three or six ketamine infusions (0.5 mg/kg over 40...
متن کاملKetamine for treatment-resistant depression: recent developments and clinical applications.
Approximately one-third of patients with major depressive disorder (MDD) do not respond to existing antidepressants, and those who do generally take weeks to months to achieve a significant effect. There is a clear unmet need for rapidly acting and more efficacious treatments. We will review recent developments in the study of ketamine, an old anaesthetic agent which has shown significant promi...
متن کاملA randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression.
Antagonism of N-methyl-D-aspartate glutamatergic receptors (NMDAR) may represent an effective antidepressant mechanism. D-cycloserine (DCS) is a partial agonist at the NMDAR-associated glycine modulatory site that at high doses acts as a functional NMDAR antagonist. Twenty-six treatment-resistant major depressive disorder patients participated in a double blind, placebo-controlled, 6-wk paralle...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The Journal of clinical psychiatry
دوره 76 6 شماره
صفحات -
تاریخ انتشار 2015